How I Treat AML: Which Patients Might Benefit from Hypomethylating Agents in the Frontline and at Relapse?
Gail J. Roboz, MD, Weill Cornell Medical College
Saturday, September 9, 2017 11:25 a.m.
Fairmont Chicago, Millennium Park, Chicago, IL
Though hypomethylating agents (HMAs) have been available for about half a century, their use in acute myeloid leukemia (AML) has increased dramatically over the last decade. Clinicians are faced with difficult choices as to when these drugs should be used in patients with AML, in whom, for what period of time, and combined with what other agents. The objective of this presentation is to tackle these questions using challenging cases that highlight the latest clinical, molecular, and translational data.
About the Speaker
Gail J. Roboz, MD, is Professor of Medicine and Director of the Clinical and Translational Leukemia Programs at the Weill Medical College of Cornell University and the New York Presbyterian Hospital in New York City. She has an active clinical practice for patients with acute and chronic leukemias, myelodysplastic syndrome, bone marrow failure states, and myeloproliferative neoplasms. Her research interests are in developmental therapeutics and novel clinical trials for these areas. Dr. Roboz is the principal investigator for investigator-initiated, cooperative group, and industry-sponsored clinical trials and has authored or coauthored many manuscripts and abstracts. She sits on the editorial boards of and acts as a reviewer for several journals. She has played an active role as an invited speaker or panelist at numerous regional, national, and international conferences. Dr. Roboz also serves on the Medical Advisory Board of the Aplastic Anemia and MDS International Foundation.
back to top